The emerging class of GLP-1 receptor and GIP dual medications, including tirzepatide, semaglutide, and the relatively introduced retatrutide, represent promising advances in metabolic management . Although https://retatrutide637823.prublogger.com/42416105/retatrutide-a-thorough-look